Iacob Speranta, Chitul Mirela, Stan Diana, Gheorghe Daria, Grasu Mugur, Iacob Razvan, Gheorghe Cristian, Popescu Irinel, Gheorghe Liliana
Fundeni Clinical Institute, Bucharest, Romania.
"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
J Viral Hepat. 2025 Jun;32(6):e70034. doi: 10.1111/jvh.70034.
Given that delta hepatitis is associated with a 2-6 times higher risk for hepatocellular carcinoma (HCC) compared to HBV monoinfection, we aimed to identify the negative prognostic factors for complications associated with HDV infection (particularly HCC) and to validate BEA score as a screening tool for HCC in HDV. Our retrospective single centre study included all consecutive admissions of adult patients with chronic HDV infection in the period 01.01.2021-31.12.2022. The negative prognostic factors identified were higher MELD (p < 0.0001) and higher BEA score on admission (p < 0.0001), older age on HBV diagnosis (p < 0.0001) and advanced fibrosis when PegINF was administered (p = 0.01). Good prognostic factors were: Class A-BEA score (p = 0.001), normal platelet count (p = 0.00001), normal albumin level (p = 0.001) and prior treatment with PegInf (p = 0.01). ROC curve showed 78.5% sensitivity for BEA score > 2, validating it as a potential screening tool for HCC. Hence, for patients with BEA score > 2 imaging screening should be intensified in order to early diagnose HCC and prompt access to curative treatment. Additionally, the negative prognostic factors identified (MELD > 15, advanced fibrosis when treated with PegINF or diagnosis with HBV infection at an older age) should encourage more frequent monitoring for HCC compared to local guidelines recommendations.
鉴于与单纯乙肝病毒感染相比,丁型肝炎患者发生肝细胞癌(HCC)的风险高2至6倍,我们旨在确定丁型肝炎病毒感染相关并发症(尤其是HCC)的不良预后因素,并验证BEA评分作为丁型肝炎病毒感染患者HCC筛查工具的有效性。我们的回顾性单中心研究纳入了2021年1月1日至2022年12月31日期间所有连续入院的慢性丁型肝炎病毒感染成年患者。确定的不良预后因素包括较高的终末期肝病模型(MELD)评分(p<0.0001)、入院时较高的BEA评分(p<0.0001)、乙肝诊断时年龄较大(p<0.0001)以及使用聚乙二醇干扰素(PegINF)治疗时存在重度肝纤维化(p=0.01)。良好的预后因素为:A-BEA评分等级(p=0.001)、血小板计数正常(p=0.00001)、白蛋白水平正常(p=0.001)以及既往接受过PegInf治疗(p=0.01)。受试者工作特征(ROC)曲线显示,BEA评分>2时的敏感度为78.5%,验证了其作为HCC潜在筛查工具的有效性。因此,对于BEA评分>2的患者,应加强影像学筛查,以便早期诊断HCC并及时接受根治性治疗。此外,所确定的不良预后因素(MELD>15、使用PegINF治疗时存在重度肝纤维化或乙肝感染诊断时年龄较大)应促使对HCC的监测频率高于当地指南的建议。